Bezafibrato (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bezafibrato" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

4^th place

9^th place

799^th place

22^nd place

493^rd place

15^th place

222^nd place

243^rd place

ansa.it (Global: 493^rd place; Italian: 15^th place)

Farmaco anti-colesterolo possibile arma contro la demenza - Biotech - Ansa.it, su Agenzia ANSA, 28 agosto 2025. URL consultato il 30 agosto 2025.

doi.org (Global: 2^nd place; Italian: 7^th place)

dx.doi.org

A. Tenenbaum, M. Motro; EZ. Fisman; D. Tanne; V. Boyko; S. Behar, Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome., in Arch Intern Med, vol. 165, n. 10, maggio 2005, pp. 1154-60, DOI:10.1001/archinte.165.10.1154, PMID 15911729.
A. Tenenbaum, Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease, in Circulation, vol. 109, n. 18, 2004, pp. 2197–2202, DOI:10.1161/01.CIR.0000126824.12785.B6, PMID 15123532. URL consultato il 30 settembre 2012.
Alexander Tenenbaum, Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate, in Archives of Internal Medicine, vol. 166, n. 7, 2006, p. 737, DOI:10.1001/archinte.166.7.737, PMID15123532. URL consultato il 30 settembre 2012.
T. Teramoto, K. Shirai; H. Daida; N. Yamada, Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study., in Cardiovasc Diabetol, vol. 11, 2012, p. 29, DOI:10.1186/1475-2840-11-29, PMID 22439599.
(EN) Federica Cordella, Lorenza Mautone e Debora Salerno, Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia, in Alzheimer's & Dementia, vol. 21, n. 8, 2025, pp. e70419, DOI:10.1002/alz.70419. URL consultato il 30 agosto 2025.

nih.gov (Global: 4^th place; Italian: 9^th place)

ncbi.nlm.nih.gov

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study., in Circulation, vol. 102, n. 1, luglio 2000, pp. 21-27, PMID 10880410.
A. Tenenbaum, M. Motro; EZ. Fisman; D. Tanne; V. Boyko; S. Behar, Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome., in Arch Intern Med, vol. 165, n. 10, maggio 2005, pp. 1154-60, DOI:10.1001/archinte.165.10.1154, PMID 15911729.
A. Tenenbaum, Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease, in Circulation, vol. 109, n. 18, 2004, pp. 2197–2202, DOI:10.1161/01.CIR.0000126824.12785.B6, PMID 15123532. URL consultato il 30 settembre 2012.
T. Teramoto, K. Shirai; H. Daida; N. Yamada, Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study., in Cardiovasc Diabetol, vol. 11, 2012, p. 29, DOI:10.1186/1475-2840-11-29, PMID 22439599.

oadoi.org (Global: 799^th place; Italian: 22^nd place)

A. Tenenbaum, M. Motro; EZ. Fisman; D. Tanne; V. Boyko; S. Behar, Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome., in Arch Intern Med, vol. 165, n. 10, maggio 2005, pp. 1154-60, DOI:10.1001/archinte.165.10.1154, PMID 15911729.
A. Tenenbaum, Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease, in Circulation, vol. 109, n. 18, 2004, pp. 2197–2202, DOI:10.1161/01.CIR.0000126824.12785.B6, PMID 15123532. URL consultato il 30 settembre 2012.
Alexander Tenenbaum, Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate, in Archives of Internal Medicine, vol. 166, n. 7, 2006, p. 737, DOI:10.1001/archinte.166.7.737, PMID15123532. URL consultato il 30 settembre 2012.
T. Teramoto, K. Shirai; H. Daida; N. Yamada, Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study., in Cardiovasc Diabetol, vol. 11, 2012, p. 29, DOI:10.1186/1475-2840-11-29, PMID 22439599.

wiley.com (Global: 222^nd place; Italian: 243^rd place)

onlinelibrary.wiley.com

(EN) Federica Cordella, Lorenza Mautone e Debora Salerno, Bezafibrate treatment rescues neurodevelopmental and neurodegenerative defects in 3D cortical organoid model of MAPT frontotemporal dementia, in Alzheimer's & Dementia, vol. 21, n. 8, 2025, pp. e70419, DOI:10.1002/alz.70419. URL consultato il 30 agosto 2025.